SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A fair growth of 15.74% in the revenue at Rs. 8092.00 millions was reported in the March 2024 quarter as compared to Rs. 6991.40 millions during year-ago period.A comparatively good net profit growth of 41.93% to Rs. 1258.50 millions was reported for the quarter ended March 2024 compared to Rs. 886.70 millions of previous same quarter.Operating profit surged to 2111.50 millions from the corresponding previous quarter of 1647.40 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 8092.00 6991.40 15.74 32986.40 28841.60 14.37 32986.40 28841.60 14.37
Other Income 161.00 33.00 387.88 346.80 86.50 300.92 346.80 86.50 300.92
PBIDT 2111.50 1647.40 28.17 9141.00 6733.40 35.76 9141.00 6733.40 35.76
Interest 83.20 122.60 -32.14 405.20 343.10 18.10 405.20 343.10 18.10
PBDT 2028.30 1524.80 33.02 8735.80 6390.30 36.70 8735.80 6390.30 36.70
Depreciation 397.20 305.60 29.97 1352.40 1119.90 20.76 1352.40 1119.90 20.76
PBT 1631.10 1219.20 33.78 7383.40 5270.40 40.09 7383.40 5270.40 40.09
TAX 372.60 332.50 12.06 1949.80 1381.50 41.14 1949.80 1381.50 41.14
Deferred Tax 93.40 109.00 -14.31 494.90 548.00 -9.69 494.90 548.00 -9.69
PAT 1258.50 886.70 41.93 5433.60 3888.90 39.72 5433.60 3888.90 39.72
Equity 155.20 154.80 0.26 155.20 154.80 0.26 155.20 154.80 0.26
PBIDTM(%) 26.09 23.56 10.74 27.71 23.35 18.70 27.71 23.35 18.70

JB Chem & Pharma Share Price

1978.00 -20.65 (-1.03%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×